Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change +0.64
Percentage change 0.83	%

Held by: VTI VB VXF VBK IBB IWP SCHA FBT IWF IWR

Index	-	P/E	-	EPS (ttm)	-0.86	Insider Own	6.53%	Shs Outstand	105.67M	Perf Week	2.96%
Market Cap	8.20B	Forward P/E	120.13	EPS next Y	0.65	Insider Trans	-4.57%	Shs Float	98.77M	Perf Month	2.54%
Income	-84.30M	PEG	-	EPS next Q	-0.17	Inst Own	91.60%	Short Float	2.46%	Perf Quarter	1.35%
Sales	564.53M	P/S	14.53	EPS this Y	59.59%	Inst Trans	1.75%	Short Ratio	2.58	Perf Half Y	13.50%
Book/sh	10.84	P/B	7.16	EPS next Y	209.50%	ROA	-8.29%	Short Interest	2.43M	Perf Year	42.56%
Cash/sh	9.70	P/C	8.00	EPS next 5Y	-	ROE	-9.63%	52W Range	45.50 - 84.89	Perf YTD	8.36%
Dividend Est.	-	P/FCF	-	EPS past 5Y	12.47%	ROI	-7.28%	52W High	-8.58%	Beta	1.00
Dividend TTM	-	Quick Ratio	7.69	Sales past 5Y	7617.73%	Gross Margin	92.72%	52W Low	70.57%	ATR (14)	1.94
Dividend Ex-Date	-	Current Ratio	7.81	EPS Y/Y TTM	55.51%	Oper. Margin	-19.93%	RSI (14)	63.34	Volatility	2.25% 2.29%
Employees	610	Debt/Eq	0.02	Sales Y/Y TTM	54.31%	Profit Margin	-14.93%	Recom	1.35	Target Price	96.13
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	64.92%	Payout	-	Rel Volume	0.90	Prev Close	76.97
Sales Surprise	2.21%	EPS Surprise	15.88%	Sales Q/Q	45.67%	Earnings	Aug 07 BMO	Avg Volume	938.21K	Price	77.61
SMA20	4.70%	SMA50	2.42%	SMA200	10.09%	Trades		Volume	845,753	Change	0.83%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-06-24	Upgrade	Piper Sandler	Neutral → Overweight	$68 → $92
Jan-03-24	Initiated	Robert W. Baird	Outperform	$83
Dec-11-23	Initiated	TD Cowen	Outperform	$75
Apr-20-23	Initiated	Morgan Stanley	Overweight	$80
Aug-22-22	Downgrade	Goldman	Buy → Neutral	$64 → $49
Jul-07-22	Initiated	Mizuho	Buy	$74
Jun-14-22	Initiated	UBS	Buy	$75
Apr-22-22	Initiated	Piper Sandler	Neutral	$59
Feb-16-22	Initiated	Goldman	Buy	$64
Sep-23-21	Initiated	Needham	Buy	$55
Dec-15-20	Initiated	BofA Securities	Buy	$40
Dec-10-20	Initiated	Goldman	Buy	$38
Feb-20-20	Initiated	Evercore ISI	Outperform
Jan-31-20	Downgrade	JP Morgan	Overweight → Neutral	$26
Dec-24-19	Reiterated	Canaccord Genuity	Buy	$29 → $65
Aug-12-19	Initiated	Jefferies	Buy	$16
Feb-26-18	Initiated	JP Morgan	Overweight
Feb-08-18	Initiated	RBC Capital Mkts	Outperform	$33
Dec-15-17	Initiated	Canaccord Genuity	Buy	$31
Nov-08-17	Upgrade	SunTrust	Hold → Buy

Show Previous Ratings

Sep-06-24 11:31AM	Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report? (Zacks)
Sep-05-24 01:12AM	Intra-Cellular Therapies, Inc. (ITCI): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-28-24 08:00AM	Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 11:06AM	Biotech Stock Pulls Back After Earnings Report; Profits On The Horizon (Investor's Business Daily)
09:54AM	Loading…
09:54AM	Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat (Zacks)
08:00AM	Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire)
Aug-07-24 04:14PM	Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains' (Investor's Business Daily) -5.81%
08:45AM	Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:41AM	Intra-Cellular: Q2 Earnings Snapshot (Associated Press Finance)
07:40AM	Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer (GlobeNewswire)
07:30AM	Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance (GlobeNewswire)
Jul-31-24 10:01AM	Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-24-24 08:00AM	Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast (GlobeNewswire)
Jul-09-24 09:55AM	Wall Street Analysts See a 30.14% Upside in Intra-Cellular (ITCI): Can the Stock Really Move This High? (Zacks)
09:52AM	Loading…
Jun-24-24 09:52AM	Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe (Zacks)
Jun-20-24 02:37PM	Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87 (Investor's Business Daily)
Jun-19-24 10:27AM	Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals (Zacks)
06:27AM	Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock? (Zacks)
Jun-18-24 04:22PM	Intra-Cellular Therapies Eyes $1.7 Billion Opportunity After Phase 3 Win (Investor's Business Daily) +9.60%
01:34PM	Intra-Cellular Therapies edges closer to FDA win for Caplyta in depression (Clinical Trials Arena)
07:30AM	Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder (GlobeNewswire)
07:30AM	Intra-Cellular depression drug succeeds in second late-stage study (BioPharma Dive)
Jun-10-24 08:00AM	Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
Jun-06-24 11:31AM	Why Is Intra-Cellular (ITCI) Up 1.2% Since Last Earnings Report? (Zacks)
May-30-24 06:00AM	The Secret Stock Stash: 3 Overlooked Picks That Belong in Every Portfolio (InvestorPlace)
May-29-24 08:00AM	Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-27-24 06:34PM	Hedge Funds Like Intra-Cellular Therapies (NASDAQ:ITCI) (Insider Monkey)
06:13PM	7 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
May-23-24 08:00AM	Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting (GlobeNewswire)
03:44PM	Loading…
May-08-24 03:44PM	Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2024 Earnings Call Transcript (Insider Monkey) -5.91%
11:43AM	Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates (Zacks)
08:00AM	Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
03:13AM	Intra-Cellular Therapies Inc (ITCI) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ... (GuruFocus.com)
May-07-24 09:18AM	Sector Update: Health Care Stocks Steady Pre-Bell Tuesday (MT Newswires)
09:12AM	Intra-Cellular Therapies Surpasses Q1 Revenue Estimates with Strong CAPLYTA Sales (GuruFocus.com)
08:40AM	Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:16AM	Intra-Cellular Therapies' Q1 Net Loss Narrows, Net Total Revenue Rises (MT Newswires)
07:37AM	Intra-Cellular: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Intra-Cellular Therapies Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-30-24 08:00AM	Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast (GlobeNewswire)
Apr-25-24 10:01AM	Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-24-24 04:01PM	Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
11:36AM	3 Biotech Stocks With Skyrocketing Potential: April 2024 (InvestorPlace)
11:31AM	Alexandria Real Estate Equities, Inc. (NYSE:ARE) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-22-24 11:10AM	10 Best Performing Biotech ETFs in 2024 (Insider Monkey)
Apr-17-24 08:46PM	Intra-Cellular Therapies Prices Public Offering of Common Stock (GlobeNewswire) -6.12%
09:44AM	Biotech Leader Intra-Cellular Soars 23%, Breaks Out Past Latest Buy Point (Investor's Business Daily)
09:21AM	Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals (Zacks)
07:36AM	Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last? (Zacks)
Apr-16-24 04:06PM	Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock (GlobeNewswire) +23.29%
04:00PM	Intra-Cellular Launches 23% To Record High, Breaking Out After Depression Drug Scores Big (Investor's Business Daily)
12:19PM	UnitedHealth Group, Morgan Stanley rise; PNC Financial, Live Nation fall, Tuesday, 4/16/2024 (Associated Press)
09:08AM	Intra-Cellular Therapies Stock Launches 20% Into Breakout Territory On Depression Test Results (Investor's Business Daily)
07:14AM	Intra-Cellular builds case for depression drug with late-stage trial win (BioPharma Dive)
07:00AM	Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder (GlobeNewswire)
Mar-19-24 08:30AM	Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes (GlobeNewswire)
Mar-12-24 01:16AM	Intra-Cellular Therapies Inc Chairman, President & CEO Sharon Mates Sells 61,277 Shares (GuruFocus.com)
Mar-06-24 08:00AM	Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey) -5.96%
Feb-28-24 05:01AM	EVP and General Counsel Michael Halstead Sells Shares of Intra-Cellular Therapies Inc (GuruFocus.com)
Feb-27-24 08:00AM	Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-23-24 11:59AM	Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:41AM	Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss (Zacks)
Feb-22-24 07:59AM	Intra-Cellular: Q4 Earnings Snapshot (Associated Press Finance)
07:53AM	Intra-Cellular Therapies Inc (ITCI) Reports Robust Revenue Growth in 2023 Earnings (GuruFocus.com)
07:30AM	Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update (GlobeNewswire)
Feb-15-24 10:00AM	Intra-Cellular Therapies (ITCI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Feb-13-24 11:51AM	Biotech Leader Intra-Cellular Therapies Nears Buy Point Ahead Of Earnings Report (Investor's Business Daily)
Feb-10-24 03:07PM	Stock Market Today: Nasdaq Hot, But Watch Out For This; Cathie Wood Play Leads 5 New Buys (Investor's Business Daily)
Feb-08-24 08:00AM	Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast (GlobeNewswire)
Feb-05-24 11:11PM	Intra-Cellular Therapies Inc EVP, Chief Medical Officer Suresh Durgam Sells 6,167 Shares (GuruFocus.com)
Jan-18-24 09:01PM	Intra-Cellular Therapies Inc CEO Sharon Mates Sells 191,362 Shares (GuruFocus.com)
Jan-12-24 07:02PM	Intra-Cellular Therapies Inc EVP and General Counsel Michael Halstead Sells 50,000 Shares (GuruFocus.com)
09:23AM	16 Best Mid-Cap Growth Stocks To Buy Now (Insider Monkey)
Jan-05-24 11:02AM	Intra-Cellular Therapies Inc EVP Suresh Durgam Sells 62,282 Shares (GuruFocus.com)
Jan-02-24 08:00AM	Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-01-24 09:55AM	Intra-Cellular Therapies (ITCI) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Dec-20-23 02:15PM	11 Most Promising Psychedelic Stocks According to Hedge Funds (Insider Monkey)
Dec-19-23 12:00PM	Intra-Cellular Therapies (ITCI) is a Great Momentum Stock: Should You Buy? (Zacks)
Dec-16-23 03:02PM	Intra-Cellular Therapies Inc's EVP, Chief Medical Officer Suresh Durgam Sells 21,262 Shares (GuruFocus.com)
Dec-13-23 01:11PM	IBD 50 Stocks To Watch: Biotech Leader Intra-Cellular Therapies Is Breaking Out Past A New Buy Point (Investor's Business Daily)
Dec-05-23 08:00AM	Intra-Cellular Therapies Highlights Data Presentations at the American College of Neuropsychopharmacology Annual Meeting (GlobeNewswire)
Nov-23-23 09:55AM	Wall Street Analysts Think Intra-Cellular (ITCI) Could Surge 33.02%: Read This Before Placing a Bet (Zacks)
Nov-15-23 04:31PM	15 Developed Countries with Lowest Autism Rates (Insider Monkey)
08:00AM	Intra-Cellular Therapies to Present at the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
01:03AM	Insider Sell Alert: EVP Michael Halstead Sells 50,000 Shares of Intra-Cellular Therapies Inc (ITCI) (GuruFocus.com)
Nov-07-23 09:55AM	Wall Street Analysts Believe Intra-Cellular (ITCI) Could Rally 41.19%: Here's is How to Trade (Zacks)
Nov-03-23 02:51PM	Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 10:17AM	Intra-Cellular Therapies Inc (ITCI) Reports Q3 2023 Earnings, Raises Sales Guidance (GuruFocus.com)
07:40AM	Intra-Cellular: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance (GlobeNewswire)
Oct-31-23 08:00AM	Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences (GlobeNewswire) +7.31%
Oct-29-23 07:00AM	I'm Targeting Intra-Cellular Therapies for a Covered-Call Play (TheStreet.com)
Oct-26-23 10:02AM	Intra-Cellular Therapies (ITCI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
08:00AM	Intra-Cellular Therapies to Host Third Quarter 2023 Financial Results Conference Call and Webcast (GlobeNewswire)
Sep-20-23 08:00AM	Intra-Cellular Therapies to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
05:05AM	Insider Sell: Sharon Mates Sells 100,000 Shares of Intra-Cellular Therapies Inc (GuruFocus.com)
Sep-11-23 08:00AM	Intra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed Features (GlobeNewswire)
Sep-05-23 08:00AM	Intra-Cellular Therapies to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm's lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ALEXANDRIA VENTURE INVESTMENTS	Director	Sep 06 '24	Proposed Sale	73.17	25,000	1,829,178		Sep 06 05:43 PM
Mates Sharon	Chairman and CEO	Aug 29 '24	Option Exercise	12.73	35,604	453,239	1,105,933	Aug 30 06:01 PM
Mates Sharon	Chairman and CEO	Aug 30 '24	Option Exercise	12.73	34,396	437,861	1,104,725	Aug 30 06:01 PM
Mates Sharon	Chairman and CEO	Aug 29 '24	Sale	72.57	35,604	2,583,884	1,070,329	Aug 30 06:01 PM
Mates Sharon	Chairman and CEO	Aug 30 '24	Sale	72.84	34,396	2,505,351	1,070,329	Aug 30 06:01 PM
Mates Sharon	Officer	Aug 30 '24	Proposed Sale	72.78	34,396	2,503,218		Aug 30 04:06 PM
Mates Sharon	Officer	Aug 29 '24	Proposed Sale	72.51	35,604	2,581,677		Aug 29 04:34 PM
Mates Sharon	Chairman and CEO	Aug 27 '24	Option Exercise	17.57	40,513	711,813	1,110,842	Aug 28 06:00 PM
Mates Sharon	Chairman and CEO	Aug 28 '24	Option Exercise	17.57	32,699	574,521	1,103,028	Aug 28 06:00 PM
Mates Sharon	Chairman and CEO	Aug 26 '24	Option Exercise	17.57	22,713	399,067	1,093,042	Aug 28 06:00 PM
Mates Sharon	Chairman and CEO	Aug 27 '24	Sale	73.58	40,513	2,981,056	1,070,329	Aug 28 06:00 PM
Mates Sharon	Chairman and CEO	Aug 28 '24	Sale	72.75	32,699	2,378,801	1,070,329	Aug 28 06:00 PM
Mates Sharon	Chairman and CEO	Aug 26 '24	Sale	74.59	22,713	1,694,229	1,070,329	Aug 28 06:00 PM
Mates Sharon	Officer	Aug 28 '24	Proposed Sale	72.69	32,699	2,376,774		Aug 28 04:34 PM
Mates Sharon	Officer	Aug 27 '24	Proposed Sale	73.52	40,513	2,978,542		Aug 27 04:22 PM
Mates Sharon	Officer	Aug 26 '24	Proposed Sale	74.53	22,713	1,692,819		Aug 26 04:36 PM
Mates Sharon	Chairman and CEO	Aug 21 '24	Option Exercise	17.57	53,013	931,438	1,123,342	Aug 23 06:00 PM
Mates Sharon	Chairman and CEO	Aug 22 '24	Option Exercise	17.57	39,380	691,907	1,109,709	Aug 23 06:00 PM
Mates Sharon	Chairman and CEO	Aug 23 '24	Option Exercise	17.57	28,680	503,908	1,099,009	Aug 23 06:00 PM
Mates Sharon	Chairman and CEO	Aug 21 '24	Sale	75.65	53,013	4,010,501	1,070,329	Aug 23 06:00 PM
Mates Sharon	Chairman and CEO	Aug 22 '24	Sale	74.68	39,380	2,940,802	1,070,329	Aug 23 06:00 PM
Mates Sharon	Chairman and CEO	Aug 23 '24	Sale	74.46	28,680	2,135,435	1,070,329	Aug 23 06:00 PM
Mates Sharon	Officer	Aug 23 '24	Proposed Sale	74.40	28,680	2,133,656		Aug 23 04:14 PM
Mates Sharon	Officer	Aug 22 '24	Proposed Sale	74.62	39,380	2,938,358		Aug 22 04:09 PM
Mates Sharon	Officer	Aug 21 '24	Proposed Sale	75.59	53,013	4,007,208		Aug 21 04:25 PM
Neumann Mark	EVP, Chief Commercial Officer	Aug 16 '24	Option Exercise	36.89	18,714	690,359	48,414	Aug 20 06:03 PM
Neumann Mark	EVP, Chief Commercial Officer	Aug 16 '24	Sale	75.08	18,714	1,405,047	29,700	Aug 20 06:03 PM
Neumann Mark	Officer	Aug 16 '24	Proposed Sale	75.02	18,714	1,403,972		Aug 16 04:04 PM
RIGGS RORY B	Director	Jun 24 '24	Option Exercise	16.86	20,000	337,200	121,062	Jun 25 06:04 PM
RIGGS RORY B	Director	Jun 24 '24	Sale	75.57	4,462	337,193	116,600	Jun 25 06:04 PM
VAN NOSTRAND ROBERT L	Director	Jun 18 '24	Option Exercise	16.86	20,000	337,200	29,690	Jun 21 06:00 PM
VAN NOSTRAND ROBERT L	Director	Jun 18 '24	Sale	75.91	20,000	1,518,199	9,690	Jun 21 06:00 PM
Mates Sharon	Chairman and CEO	Apr 24 '24	Option Exercise	17.26	20,020	345,618	1,070,329	Apr 25 05:08 PM
RIGGS RORY B	Director	Mar 20 '24	Option Exercise	18.56	20,000	371,200	99,235	Mar 22 04:12 PM
Mates Sharon	Chairman, President & CEO	Mar 07 '24	Sale	66.50	40,712	2,707,277	1,050,309	Mar 11 08:33 PM
Mates Sharon	Chairman, President & CEO	Mar 11 '24	Sale	65.21	20,565	1,341,123	1,050,309	Mar 11 08:33 PM
Hineline Lawrence J.	SVP of Finance, CFO	Mar 10 '24	Option Exercise	56.73	4,539	257,497	4,539	Mar 11 08:33 PM
Hineline Lawrence J.	SVP of Finance, CFO	Mar 07 '24	Sale	66.60	13,132	874,560	0	Mar 11 08:33 PM
Hineline Lawrence J.	SVP of Finance, CFO	Mar 11 '24	Sale	65.96	10,121	667,587	0	Mar 11 08:33 PM
Halstead Michael	EVP and General Counsel	Mar 07 '24	Sale	66.15	13,132	868,698	0	Mar 11 08:32 PM
Halstead Michael	EVP and General Counsel	Mar 11 '24	Sale	65.97	7,345	484,537	0	Mar 11 08:32 PM
Neumann Mark	EVP, Chief Commercial Officer	Mar 07 '24	Sale	66.57	13,132	874,179	29,700	Mar 11 08:31 PM
Neumann Mark	EVP, Chief Commercial Officer	Mar 11 '24	Sale	65.61	7,345	481,931	29,700	Mar 11 08:31 PM
Durgam Suresh K.	EVP, Chief Medical Officer	Mar 07 '24	Sale	66.56	6,450	429,308	16,170	Mar 11 08:31 PM
Durgam Suresh K.	EVP, Chief Medical Officer	Mar 11 '24	Sale	65.59	3,712	243,482	19,803	Mar 11 08:31 PM
VAN NOSTRAND ROBERT L	Director	Feb 27 '24	Option Exercise	18.56	20,000	371,200	29,611	Feb 28 07:41 PM
VAN NOSTRAND ROBERT L	Director	Feb 27 '24	Sale	72.93	20,000	1,458,650	9,611	Feb 28 07:41 PM
Halstead Michael	EVP and General Counsel	Feb 26 '24	Sale	69.53	7,907	549,784	0	Feb 27 08:00 PM
Hineline Lawrence J.	SVP of Finance, CFO	Feb 26 '24	Option Exercise	36.89	5,882	216,987	5,882	Feb 27 08:00 PM
Hineline Lawrence J.	SVP of Finance, CFO	Feb 26 '24	Sale	69.43	13,337	925,961	0	Feb 27 08:00 PM
Mates Sharon	Chairman, President & CEO	Feb 26 '24	Sale	69.79	22,590	1,576,464	1,050,309	Feb 27 07:59 PM
Durgam Suresh K.	EVP, Chief Medical Officer	Feb 26 '24	Sale	70.17	4,112	288,534	9,488	Feb 27 07:58 PM
Neumann Mark	EVP, Chief Commercial Officer	Feb 26 '24	Sale	70.13	7,907	554,491	29,700	Feb 27 07:58 PM
MARCUS JOEL S	Director	Feb 26 '24	Option Exercise	48.93	36,757	1,798,678	65,990	Feb 27 07:57 PM
MARCUS JOEL S	Director	Feb 26 '24	Sale	68.68	26,328	1,808,253	39,662	Feb 27 07:57 PM
Halstead Michael	EVP and General Counsel	Feb 02 '24	Sale	66.42	11,860	787,719	0	Feb 05 06:13 PM
Mates Sharon	Chairman, President & CEO	Feb 02 '24	Sale	67.07	33,885	2,272,694	1,050,309	Feb 05 06:10 PM
Neumann Mark	EVP, Chief Commercial Officer	Feb 02 '24	Sale	67.15	11,860	796,367	29,700	Feb 05 06:07 PM
Hineline Lawrence J.	SVP of Finance, CFO	Feb 02 '24	Sale	66.62	11,183	745,037	0	Feb 05 06:05 PM
Durgam Suresh K.	EVP, Chief Medical Officer	Feb 02 '24	Sale	67.19	6,167	414,355	5,693	Feb 05 06:02 PM
Mates Sharon	Chairman, President & CEO	Jan 16 '24	Option Exercise	16.86	75,361	1,270,586	1,125,670	Jan 18 07:47 PM
Mates Sharon	Chairman, President & CEO	Jan 18 '24	Option Exercise	16.86	67,917	1,145,081	1,118,226	Jan 18 07:47 PM
Mates Sharon	Chairman, President & CEO	Jan 17 '24	Option Exercise	16.86	48,084	810,696	1,098,393	Jan 18 07:47 PM
Mates Sharon	Chairman, President & CEO	Jan 16 '24	Sale	67.25	75,361	5,067,982	1,050,309	Jan 18 07:47 PM
Mates Sharon	Chairman, President & CEO	Jan 18 '24	Sale	65.19	67,917	4,427,848	1,050,309	Jan 18 07:47 PM
Mates Sharon	Chairman, President & CEO	Jan 17 '24	Sale	66.24	48,084	3,185,062	1,050,309	Jan 18 07:47 PM
Halstead Michael	EVP and General Counsel	Jan 11 '24	Option Exercise	13.60	50,000	680,051	50,000	Jan 12 06:02 PM
Halstead Michael	EVP and General Counsel	Jan 11 '24	Sale	66.83	50,000	3,341,699	0	Jan 12 06:02 PM
Durgam Suresh K.	EVP, Chief Medical Officer	Jan 02 '24	Option Exercise	19.87	62,282	1,237,543	62,282	Jan 04 07:54 PM
Durgam Suresh K.	EVP, Chief Medical Officer	Jan 02 '24	Sale	70.60	62,282	4,397,113	0	Jan 04 07:54 PM
Durgam Suresh K.	EVP, Chief Medical Officer	Dec 13 '23	Sale	65.00	21,262	1,382,030	0	Dec 15 05:01 PM
Neumann Mark	EVP, Chief Commercial Officer	Nov 06 '23	Option Exercise	23.94	26,754	640,491	72,093	Nov 08 05:31 PM
Neumann Mark	EVP, Chief Commercial Officer	Nov 06 '23	Sale	55.63	42,393	2,358,152	29,700	Nov 08 05:31 PM

Open in Screener

RPRX

Royalty Pharma plc

Sep 20 • 04:00PM ET

27.54

Dollar change -0.45
Percentage change -1.61	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

RPRX Royalty Pharma plc daily Stock Chart

Held by: VTI VO VXF VTV VOE VYM VHT IWR IHE IWD

Index	-	P/E	18.33	EPS (ttm)	1.50	Insider Own	14.69%	Shs Outstand	446.69M	Perf Week	-0.65%
Market Cap	12.34B	Forward P/E	6.27	EPS next Y	4.39	Insider Trans	0.00%	Shs Float	382.30M	Perf Month	-0.22%
Income	672.90M	PEG	5.73	EPS next Q	0.92	Inst Own	70.75%	Short Float	3.84%	Perf Quarter	2.34%
Sales	2.24B	P/S	5.52	EPS this Y	-11.85%	Inst Trans	1.54%	Short Ratio	5.60	Perf Half Y	-9.50%
Book/sh	14.42	P/B	1.91	EPS next Y	11.17%	ROA	3.88%	Short Interest	14.68M	Perf Year	0.33%
Cash/sh	4.02	P/C	6.84	EPS next 5Y	3.20%	ROE	10.56%	52W Range	25.20 - 31.66	Perf YTD	-1.96%
Dividend Est.	0.92 (3.34%)	P/FCF	4.59	EPS past 5Y	2.23%	ROI	4.78%	52W High	-13.00%	Beta	0.46
Dividend TTM	0.83 (3.01%)	Quick Ratio	9.35	Sales past 5Y	5.78%	Gross Margin	-	52W Low	9.29%	ATR (14)	0.51
Dividend Ex-Date	Aug 16, 2024	Current Ratio	9.35	EPS Y/Y TTM	165.78%	Oper. Margin	42.92%	RSI (14)	42.91	Volatility	1.57% 1.66%
Employees	89	Debt/Eq	1.17	Sales Y/Y TTM	-5.25%	Profit Margin	30.07%	Recom	1.33	Target Price	44.43
Option/Short	Yes / Yes	LT Debt/Eq	1.17	EPS Q/Q	-55.20%	Payout	31.57%	Rel Volume	2.21	Prev Close	27.99
Sales Surprise	-3.10%	EPS Surprise	-0.39%	Sales Q/Q	-0.17%	Earnings	Aug 08 BMO	Avg Volume	2.62M	Price	27.54
SMA20	-2.97%	SMA50	-1.41%	SMA200	-2.61%	Trades		Volume	5,783,149	Change	-1.61%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-03-24	Downgrade	UBS	Buy → Neutral	$28
Jun-14-22	Resumed	UBS	Buy	$47
May-13-22	Initiated	Scotiabank	Sector Outperform	$53
Apr-27-22	Initiated	Goldman	Buy	$56
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight	$50
Apr-06-22	Resumed	Morgan Stanley	Overweight	$48
Oct-29-21	Upgrade	Citigroup	Neutral → Buy	$50
Jul-30-21	Initiated	Tigress Financial	Buy	$50
Nov-09-20	Upgrade	UBS	Neutral → Buy	$52 → $51
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	UBS	Neutral	$52
Jul-13-20	Initiated	SunTrust	Buy	$56
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight	$51
Jul-13-20	Initiated	JP Morgan	Neutral	$50
Jul-13-20	Initiated	Goldman	Neutral	$47
Jul-13-20	Initiated	Cowen	Outperform	$55
Jul-13-20	Initiated	Citigroup	Neutral	$50
Jul-13-20	Initiated	BofA Securities	Buy	$55

Show Previous Ratings

Sep-03-24 05:14PM	Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement (GlobeNewswire)
05:06PM	Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement (GlobeNewswire)
Aug-28-24 04:15PM	Royalty Pharma to Present at Morgan Stanley's 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-26-24 06:16AM	Jim Cramer on Royalty Pharma plc (NASDAQ:RPRX): Its Been a Bit of a Bust, I Feel Badly (Insider Monkey)
Aug-23-24 05:32AM	Jim Cramer's Latest Lightning Round: Top 10 Stocks (Insider Monkey)
03:58PM	Loading…
Aug-17-24 03:58PM	Why Is Royalty Pharma plc (RPRX) the Best Defensive Stock to Buy Now? (Insider Monkey)
Aug-16-24 06:09PM	10 Best Defensive Stocks To Buy Now (Insider Monkey)
Aug-09-24 01:05AM	Royalty Pharma PLC (RPRX): A Strategic SWOT Insight (GuruFocus.com)
Aug-08-24 04:16PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
07:00AM	Royalty Pharma Reports Second Quarter 2024 Results (GlobeNewswire)
Jul-24-24 08:30AM	Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital (GlobeNewswire)
Jul-19-24 08:15AM	Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024 (GlobeNewswire)
Jul-17-24 04:15PM	Royalty Pharma Declares Third Quarter 2024 Dividend (GlobeNewswire)
Jul-15-24 12:10PM	Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jul-02-24 07:44PM	Is Royalty Pharma plc (RPRX) a Good Stock to Buy Now? (Insider Monkey)
06:58PM	Loading…
06:58PM	10 Best Undervalued Stocks To Buy Now (Insider Monkey)
Jun-26-24 06:00AM	Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024 (InvestorPlace)
Jun-24-24 12:56PM	7 Biotech Stocks to Buy on the Dip: June 2024 (InvestorPlace)
Jun-05-24 06:14AM	June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge (InvestorPlace)
Jun-04-24 04:15PM	Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-03-24 05:15PM	Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes (GlobeNewswire)
May-28-24 07:10AM	Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million (GlobeNewswire)
May-27-24 06:28PM	Is Cytokinetics, Incorporated (NASDAQ:CYTK) the Best Mid-Cap Healthcare Stock To Buy Now? (Insider Monkey)
May-25-24 11:10PM	20 Biggest Publicly Traded Biotech Companies (Insider Monkey)
May-22-24 04:10PM	Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline (GlobeNewswire)
04:00PM	Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline (GlobeNewswire)
May-20-24 02:41PM	7 Dividend Stocks to Buy at a 52-Week Low (InvestorPlace)
May-13-24 08:15AM	Royalty Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
May-10-24 01:07AM	Royalty Pharma PLC (RPRX): A Strategic SWOT Insight (GuruFocus.com)
May-09-24 03:35PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
12:00PM	Loading…
12:00PM	Royalty Pharma (RPRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
11:56AM	RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
10:46AM	Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:10AM	Royalty Pharma (RPRX) Beats Q1 Earnings and Revenue Estimates (Zacks)
07:00AM	Royalty Pharma Reports First Quarter 2024 Results (GlobeNewswire)
06:45AM	Royalty Pharma to Acquire Royalty Interest in Sanofi's Frexalimab (GlobeNewswire)
May-08-24 08:51AM	Why Earnings Season Could Be Great for Royalty Pharma (RPRX) (Zacks)
May-06-24 09:16AM	Insights Into Royalty Pharma (RPRX) Q1: Wall Street Projections for Key Metrics (Zacks)
May-02-24 04:01PM	Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma (Business Wire)
10:01AM	Royalty Pharma (RPRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-30-24 08:37AM	PureTech Health plc (NASDAQ:PRTC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-19-24 08:15AM	Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire)
Apr-17-24 08:15AM	Royalty Pharma Declares Second Quarter 2024 Dividend (GlobeNewswire)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Feb-28-24 04:15PM	Royalty Pharma to Present at TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Feb-20-24 12:45PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Feb-17-24 12:15AM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Feb-16-24 03:30PM	Royalty Pharma (RPRX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
09:45AM	Royalty Pharma plc (NASDAQ:RPRX) Q4 2023 Earnings Call Transcript (Insider Monkey)
12:04AM	Royalty Pharma PLC (RPRX): A Strategic SWOT Insight (GuruFocus.com)
Feb-15-24 11:08PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
07:58AM	Royalty Pharma PLC (RPRX) Earnings Report: A Detailed Analysis (GuruFocus.com)
07:30AM	Royalty Pharma Reports Q4 and Full Year 2023 Results (GlobeNewswire)
Jan-31-24 01:04AM	What Makes Royalty Pharma plc (RPRX) a Compelling Stock? (Insider Monkey)
Jan-30-24 04:15PM	Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024 (GlobeNewswire)
Jan-19-24 08:15AM	Royalty Pharma Announces Dividend Increase (GlobeNewswire)
Jan-08-24 07:00AM	Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 05:30AM	Should You Sell Royalty Pharma plc (RPRX)? (Insider Monkey)
Nov-27-23 04:15PM	Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference (GlobeNewswire)
Nov-13-23 08:10AM	Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program (GlobeNewswire)
08:00AM	Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program (Business Wire)
Nov-09-23 04:33PM	Royalty Pharma plc (NASDAQ:RPRX) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:15AM	The Royalty Pharma PLC (RPRX) Company: A Short SWOT Analysis (GuruFocus.com)
Nov-08-23 07:00AM	Royalty Pharma Reports Third Quarter 2023 Results (GlobeNewswire)
Oct-19-23 07:59AM	Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi (GlobeNewswire)
Oct-16-23 04:15PM	Royalty Pharma Declares Fourth Quarter 2023 Dividend (GlobeNewswire)
Oct-11-23 04:15PM	Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023 (GlobeNewswire)
Sep-21-23 08:25AM	Royalty Pharma Appoints Eric Schneider as Chief Technology Officer (GlobeNewswire)
Sep-05-23 04:15PM	Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement (GlobeNewswire)
04:01PM	Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement (GlobeNewswire)
08:25AM	Royalty Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-24-23 06:30AM	Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg) (GlobeNewswire)
Aug-08-23 07:00AM	Royalty Pharma Reports Second Quarter 2023 Results (GlobeNewswire)
Jul-18-23 04:15PM	Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023 (GlobeNewswire)
Jul-17-23 04:15PM	Royalty Pharma Declares Third Quarter 2023 Dividend (GlobeNewswire)
Jun-18-23 08:58AM	Institutional owners may consider drastic measures as Royalty Pharma plc's (NASDAQ:RPRX) recent US$453m drop adds to long-term losses (Simply Wall St.)
Jun-07-23 08:15AM	Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
May-22-23 07:52PM	Goldman Sachs Likes These 2 Stocks, Insiders Just Poured Millions Into Them Heres Why You Might Want to Ride Their Coattails (TipRanks)
May-13-23 08:15AM	Here's Why We're Wary Of Buying Royalty Pharma's (NASDAQ:RPRX) For Its Upcoming Dividend (Simply Wall St.)
May-11-23 10:42AM	Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's (Simply Wall St.)
May-09-23 07:00AM	Royalty Pharma Reports First Quarter 2023 Results (GlobeNewswire)
May-03-23 04:15PM	Royalty Pharma To Present At The BofA Securities 2023 Health Care Conference (GlobeNewswire)
Apr-20-23 06:15AM	Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20 (Simply Wall St.)
Apr-17-23 08:15AM	Royalty Pharma Declares Second Quarter 2023 Dividend (GlobeNewswire)
Apr-13-23 09:01AM	Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023 (GlobeNewswire)
Apr-05-23 06:17AM	Is Royalty Pharma plc's (NASDAQ:RPRX) Recent Price Movement Underpinned By Its Weak Fundamentals? (Simply Wall St.)
Mar-31-23 06:36AM	Daily Vickers Top Buyers & Sellers for 03/31/2023 (Argus Research)
Mar-27-23 07:30AM	Royalty Pharma Announces $1.0 Billion Share Repurchase Program (GlobeNewswire) +5.53%
Mar-23-23 07:00AM	Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million (GlobeNewswire)
03:00AM	PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million (Business Wire)
Mar-15-23 08:00AM	Royalty Pharma Raises Full Year 2023 Guidance (GlobeNewswire)
Mar-08-23 05:16AM	Optimism around Royalty Pharma (NASDAQ:RPRX) delivering new earnings growth may be shrinking as stock declines 3.5% this past week (Simply Wall St.)
Mar-01-23 08:15AM	Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments (GlobeNewswire)
Feb-15-23 07:00AM	Royalty Pharma Reports Q4 and Full Year 2022 Results (GlobeNewswire)
Feb-09-23 04:15PM	Royalty Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-03-23 09:19AM	Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20 (Simply Wall St.)
Jan-18-23 08:25AM	Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023 (GlobeNewswire)
Jan-12-23 05:01AM	Royalty Pharma's (NASDAQ:RPRX) Shareholders Will Receive A Bigger Dividend Than Last Year (Simply Wall St.)
Jan-09-23 09:25AM	Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
09:15AM	Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis Genetic Medicines and Commercial Readiness (GlobeNewswire)

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RIGGS RORY B	Director	Jan 02 '24	Sale	28.52	235,200	6,707,081	254,899	Jan 04 05:16 PM
RIGGS RORY B	Director	Jan 03 '24	Sale	27.79	199,098	5,532,276	55,801	Jan 04 05:16 PM
RIGGS RORY B	Director	Jan 04 '24	Sale	27.55	35,702	983,504	20,099	Jan 04 05:16 PM
Avara Management Ltd	10% Owner	Dec 29 '23	Sale	28.04	65,803	1,845,406	2,477,520	Jan 03 04:31 PM
Avara Management Ltd	10% Owner	Dec 28 '23	Sale	28.20	209,863	5,918,934	2,543,323	Dec 29 04:29 PM
Avara Management Ltd	10% Owner	Dec 27 '23	Sale	28.01	41,729	1,168,754	2,753,186	Dec 29 04:29 PM
Avara Management Ltd	10% Owner	Dec 15 '23	Sale	28.01	10,229	286,499	2,794,915	Dec 19 04:30 PM
Avara Management Ltd	10% Owner	Dec 14 '23	Sale	28.91	364,441	10,534,276	2,805,144	Dec 15 04:31 PM
Avara Management Ltd	10% Owner	Dec 13 '23	Sale	28.95	307,935	8,916,012	3,169,585	Dec 15 04:31 PM

Open in Screener

CBUS

Cibus Inc

Sep 20 • 04:00PM ET

4.00

Dollar change +0.12
Percentage change 3.09	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VXF IWM IWN VTWO IWC VTWV RSSL VTHR URTY

Index	RUT	P/E	-	EPS (ttm)	-16.44	Insider Own	32.45%	Shs Outstand	20.57M	Perf Week	-27.01%
Market Cap	92.36M	Forward P/E	-	EPS next Y	-2.79	Insider Trans	-0.08%	Shs Float	15.60M	Perf Month	-45.13%
Income	-291.86M	PEG	-	EPS next Q	-0.87	Inst Own	35.81%	Short Float	13.84%	Perf Quarter	-60.00%
Sales	2.96M	P/S	31.20	EPS this Y	86.42%	Inst Trans	-16.37%	Short Ratio	9.99	Perf Half Y	-78.59%
Book/sh	11.75	P/B	0.34	EPS next Y	20.99%	ROA	-42.68%	Short Interest	2.16M	Perf Year	-79.38%
Cash/sh	1.30	P/C	3.08	EPS next 5Y	-	ROE	-77.33%	52W Range	3.58 - 23.18	Perf YTD	-79.63%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.61%	ROI	-60.04%	52W High	-82.74%	Beta	1.85
Dividend TTM	-	Quick Ratio	1.14	Sales past 5Y	837.06%	Gross Margin	-136.47%	52W Low	11.73%	ATR (14)	0.70
Dividend Ex-Date	-	Current Ratio	1.14	EPS Y/Y TTM	29.29%	Oper. Margin	-2891.76%	RSI (14)	31.79	Volatility	12.10% 12.17%
Employees	183	Debt/Eq	0.81	Sales Y/Y TTM	816.72%	Profit Margin	-9856.84%	Recom	1.50	Target Price	19.50
Option/Short	Yes / Yes	LT Debt/Eq	0.80	EPS Q/Q	62.62%	Payout	-	Rel Volume	2.22	Prev Close	3.88
Sales Surprise	78.30%	EPS Surprise	-40.17%	Sales Q/Q	325.38%	Earnings	Aug 08 AMC	Avg Volume	216.17K	Price	4.00
SMA20	-29.84%	SMA50	-47.39%	SMA200	-71.48%	Trades		Volume	480,259	Change	3.09%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-29-24	Initiated	Alliance Global Partners	Buy	$25
Jul-19-24	Resumed	Canaccord Genuity	Buy	$22
Oct-09-23	Initiated	H.C. Wainwright	Buy	$25
Jul-19-23	Resumed	Canaccord Genuity	Buy	$30

Sep-18-24 08:25AM	Cibus Announces Pricing of Public Offering of Class A Common Stock (GlobeNewswire) -28.95%
Sep-17-24 04:46PM	Cibus, Inc. Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
Sep-10-24 07:00AM	Cibus Completes First Field Trials in UK for Pod Shatter Reduction in Winter Oilseed Rape (GlobeNewswire) +9.35%
Aug-12-24 04:05PM	Cibus to Participate in Upcoming August Investor Events (GlobeNewswire) +8.77%
Aug-08-24 04:05PM	Cibus Reports Second Quarter Financial Results and Provides First Half Business Update (GlobeNewswire) -5.90%
07:36AM	Loading…
Aug-06-24 07:36AM	Cibus Achieves Positive Initial Field Trial Results for Stacked Gene Edited Herbicide Tolerant Traits in Rice (GlobeNewswire)
Aug-01-24 07:00AM	Cibus to Report Second Quarter 2024 Financial Results on August 8, 2024 After the Market Close and Host Conference Call (GlobeNewswire) -7.38%
Jun-26-24 08:30AM	Cibus Expands its Intellectual Property Coverage for Plant Gene Editing and Traits (GlobeNewswire)
Jun-17-24 07:00AM	Cibus' Confirms Important Milestone for Nutrient Use Efficiency Trait Development (GlobeNewswire)
Jun-12-24 08:00AM	Cibus Announces $13.0 Million Registered Direct Offering (GlobeNewswire)
Jun-05-24 07:00AM	Cibus to Participate in Upcoming June Investor Events (GlobeNewswire)
May-30-24 07:00AM	Cibus' White Mold (Sclerotinia) Resistance Trait Program Confirms Important Milestone for Next Generation Gene Edits in Canola (GlobeNewswire)
May-15-24 07:00AM	Canada Added to a Growing List of Countries Regulating Cibus' Gene Editing Technologies Similar to Conventional Breeding (GlobeNewswire)
May-13-24 07:00AM	Cibus to Participate in the BMO Global Farm to Market Conference (GlobeNewswire) +5.69%
May-09-24 10:55PM	CBUS Stock Earnings: Cibus Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:05PM	Loading…
04:05PM	Cibus Reports First Quarter Financial Results and Provides Business Update (GlobeNewswire)
Apr-25-24 07:00AM	Cibus to Report First Quarter 2024 Financial Results on May 9, 2024 and Host Conference Call (GlobeNewswire)
Mar-25-24 03:16PM	Cibus (CBUS) Reports Q4 Loss, Tops Revenue Estimates (Revised) (Zacks) +5.25%
Mar-22-24 01:03PM	Cibus, Inc. (NASDAQ:CBUS) Q4 2023 Earnings Call Transcript (Insider Monkey) +9.10%
Mar-21-24 08:52PM	CBUS Stock Earnings: Cibus Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -9.01%
04:05PM	Cibus Reports Fourth Quarter Financial Results and Provides Business Update (GlobeNewswire)
Mar-19-24 08:30AM	Cibus Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024 (GlobeNewswire) -6.80%
Mar-18-24 08:26AM	Cibus (CBUS) Moves 6.7% Higher: Will This Strength Last? (Zacks) +5.13%
Mar-13-24 07:35AM	Cibus to Participate in the 36th Annual Roth Conference (GlobeNewswire)
Mar-07-24 07:00AM	Cibus to Report Fourth Quarter 2023 Financial Results on March 21, 2024 and Host Conference Call (GlobeNewswire)
Feb-26-24 07:00AM	Cibus and Loveland Products Collaborate to Develop and Sell Rice Traits in the US (GlobeNewswire)
Feb-07-24 12:51PM	European Parliament Votes to Support Proposal for the Regulation of New Genomic Techniques (GlobeNewswire)
Jan-25-24 04:30PM	European Parliaments Environment Committee Votes to Support New Proposal for the Regulation of New Genomic Techniques (GlobeNewswire)
Jan-17-24 07:00AM	Cibus 2023 Field Trial Results Move Developed Traits Closer to Product Sales (GlobeNewswire)
Jan-09-24 07:00AM	Cibus Announces Major Breakthrough in Wheat Regeneration from Single Cells (GlobeNewswire) +6.27%
07:30AM	Loading…
Jan-04-24 07:30AM	Cibus Enters into a Latin America Collaboration Agreement with Interoc to deliver rice growers an innovative rice weed control system (GlobeNewswire)
Dec-12-23 07:30AM	Cibus Announces $20.3 Million Registered Direct Offering (GlobeNewswire)
Dec-01-23 08:00AM	European Union Notifies Trading Partners on the Proposal for the Regulation of Plants Obtained from New Genomic Techniques (GlobeNewswire) +10.34%
Nov-30-23 08:00AM	Cibus Announces New Publication: Industrial Scale Gene Editing in Brassica napus (GlobeNewswire)
Nov-09-23 04:05PM	Cibus Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +19.76%
Nov-06-23 08:00AM	European Parliament Releases Draft Report on the Proposal for the Regulation of Plants Obtained from New Genomic Techniques (GlobeNewswire)
Nov-02-23 04:05PM	Cibus to Report Third Quarter 2023 Financial Results on November 9, 2023 and Host Conference Call (GlobeNewswire)
Oct-09-23 09:33AM	Oracle upgraded, Spotify downgraded: Wall Street's top analyst calls (The Fly) -8.67%
Sep-18-23 05:23PM	Jim Collins to Join Cibus Board of Directors (GlobeNewswire) +15.85%
Sep-05-23 08:00AM	Cibus to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) +11.27%
Aug-09-23 05:00PM	Cibus Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -7.76%
Aug-03-23 12:30PM	Steve Berreth Appointed as General Counsel and Corporate Secretary (GlobeNewswire) +5.33%
07:00AM	Cibus to Report Second Quarter 2023 Financial Results on August 10, 2023 and Host Conference Call (GlobeNewswire)
Aug-02-23 04:05PM	Cibus to Present at the Canaccord 43rd Annual Growth Conference (GlobeNewswire)
Jul-12-23 08:30AM	Cibus Opens Dedicated, High-throughput Gene Editing Facility for Trait Production (GlobeNewswire)
Jul-05-23 04:05PM	Cibus Welcomes European Commission Proposal on Regulation of Plants Obtained from New Genomic Techniques (GlobeNewswire) +26.93% +22.32%
Jun-15-23 08:45AM	Cibus Applauds the Genetic Technology (Precision Breeding) Act 2023 Passed in the United Kingdom (GlobeNewswire) +10.78%
07:00AM	Cibus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-07-23 07:00AM	Cibus White Mold Resistance Trait in Canola Achieves Another Important Milestone (GlobeNewswire)
Jun-01-23 07:00AM	Cibus Announces Closing of Merger with Calyxt to Create Industry Leading Precision Gene Editing and Trait Development Company (GlobeNewswire) -17.30%

Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. It focuses on using gene editing to develop productivity traits in major agricultural crops such as Canola, Rice, Soybean, Corn and Wheat. The company was founded by Rory Riggs, Peter Beetham and Greg Gocal in 2010 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gocal Gregory Francis William	Chief Scientific Officer & EVP	Jul 15 '24	Sale	10.01	2,000	20,023	314,844	Jul 17 04:10 PM
Gocal Gregory Francis William	Chief Scientific Officer & EVP	Jul 12 '24	Sale	10.00	2,000	20,000	316,844	Jul 15 05:07 PM
Gocal Gregory Francis William	Chief Scientific Officer & EVP	Jun 27 '24	Sale	10.00	2,000	20,000	318,844	Jul 15 05:03 PM
RIGGS RORY B	Chief Executive Officer	Dec 12 '23	Buy	10.58	517,107	5,470,992	1,622,495	Dec 14 05:10 PM

ITCI

Intra-Cellular Therapies Inc

RPRX

Royalty Pharma plc

CBUS

Cibus Inc

Upgrade your FINVIZ experience